{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:23:27Z","timestamp":1787653407217,"version":"build-2736575974"},"reference-count":137,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM121342"],"award-info":[{"award-number":["P20GM121342"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM139769"],"award-info":[{"award-number":["P20GM139769"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Med."],"abstract":"<jats:p>Spinal Muscular Atrophy (SMA) is a rare and debilitating neurodegenerative disease characterized by the progressive loss of motor neurons in the spinal cord, leading to muscle weakness, respiratory failure, and premature mortality. The pathogenesis of SMA is highly complex and the investigation of downstream pathways and specific cellular mechanisms is still ongoing. In recent years, three FDA-approved disease-modifying therapies, nusinersen, risdiplam, and onasemnogene abeparvovec, have improved the quality of life for patients with SMA and have eased the management of associated symptoms. However, unmet needs remain as comorbidities become increasingly apparent in the era of disease-modifying therapies. Despite the remarkable progress achieved over the past decade, continued research is essential to further improve the quality of life, clinical outcomes, and standard of care for individuals living with SMA.<\/jats:p>","DOI":"10.3389\/fmmed.2026.1901311","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T09:58:16Z","timestamp":1787651896000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Spinal muscular atrophy in the disease-modifying therapy era: successes, limitations and future directions"],"prefix":"10.3389","volume":"6","author":[{"given":"Madison M.","family":"Sexton","sequence":"first","affiliation":[{"name":"Department of Bioengineering, Clemson University","place":["Clemson, SC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma W.","family":"Crow","sequence":"additional","affiliation":[{"name":"Department of Genetics and Biochemistry, Clemson University","place":["Clemson, SC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congyue Annie","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Bioengineering, Clemson University","place":["Clemson, SC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/mus.27187","article-title":"Safety and efficacy of nusinersen in spinal muscular atrophy: the EMBRACE study","volume":"63","author":"Acsadi","year":"2021","journal-title":"Muscle and Nerve"},{"key":"B2","doi-asserted-by":"publisher","first-page":"8364","DOI":"10.3390\/ijms25158364","article-title":"Physiological features of the neural stem cells obtained from an animal model of spinal muscular atrophy and their response to antioxidant curcumin","volume":"25","author":"Adami","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.4103\/2231-0770.197512","article-title":"Very severe spinal muscular atrophy (type 0)","volume":"7","author":"Al Dakhoul","year":"2017","journal-title":"Avicenna J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41551-023-01132-z","article-title":"Optimization of base editors for the functional correction of SMN2 as a treatment for spinal muscular atrophy","volume":"8","author":"Alves","year":"2024","journal-title":"Nat. Biomedical Engineering"},{"key":"B5","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s12035-013-8399-5","article-title":"Spinal muscular atrophy and the antiapoptotic role of survival of motor neuron (SMN) protein","volume":"47","author":"Anderton","year":"2013","journal-title":"Mol. Neurobiology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s11064-019-02814-4","article-title":"The protective effects of levetiracetam on a human iPSCs-Derived spinal muscular atrophy model","volume":"44","author":"Ando","year":"2019","journal-title":"Neurochem. Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1084\/jem.173.6.1407","article-title":"Human autoantibody to a novel protein of the nuclear coiled body: immunological characterization and cDNA cloning of p80-coilin","volume":"173","author":"Andrade","year":"1991","journal-title":"J. Experimental Medicine"},{"key":"B8","doi-asserted-by":"publisher","first-page":"eadg6518","DOI":"10.1126\/science.adg6518","article-title":"Base editing rescue of spinal muscular atrophy in cells and in mice","volume":"380","author":"Arbab","year":"2023","journal-title":"Sci. (New York, N.Y.)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.24497","article-title":"Spinal muscular atrophy: diagnosis and management in a new therapeutic era","volume":"51","author":"Arnold","year":"2015","journal-title":"Muscle and Nerve"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e70173","DOI":"10.1002\/jssc.70173","article-title":"Short review on currently used sample preparation and determination methods of Risdiplam","volume":"48","author":"Bali\u0144ska","year":"2025","journal-title":"J. Separation Science"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1093\/hmg\/6.11.1961","article-title":"Expression of the SMN gene, the spinal muscular atrophy determining gene, in the mammalian central nervous system","volume":"6","author":"Battaglia","year":"1997","journal-title":"Hum. Mol. Genet."},{"key":"B12","unstructured":"FDA approves new high dose regimen of SPINRAZA\u00ae (Nusinersen) for spinal muscular atrophy\n          \n          \n          2026"},{"key":"B13","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.3390\/jcm13144184","article-title":"The impact of comorbidities and motor impairment on the quality of life of patients with spinal muscular atrophy: a case\u2013control study","volume":"13","author":"B\u0142auciak","year":"2024","journal-title":"J. Clin. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1186\/s12891-025-09133-6","article-title":"Comorbidities in spinal muscular atrophy and their impact on the course of the underlying disease: a real-life observational study","volume":"26","author":"B\u0142auciak","year":"2025","journal-title":"BMC Musculoskelet. Disord."},{"key":"B15","doi-asserted-by":"publisher","first-page":"7S35","DOI":"10.1016\/S0929-693X(20)30275-X","article-title":"Functional and surgical treatments in patients with spinal muscular atrophy (SMA)","volume":"27","author":"Boulay","year":"2020","journal-title":"Arch. Pediatr. organe Off. la Soc. francaise Pediatr."},{"key":"B16","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/ana.23582","article-title":"Glucose metabolism and pancreatic defects in spinal muscular atrophy","volume":"72","author":"Bowerman","year":"2012","journal-title":"Ann. Neurology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrn2670","article-title":"Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?","volume":"10","author":"Burghes","year":"2009","journal-title":"Nat. Rev. Neurosci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e331","DOI":"10.1038\/mtna.2016.47","article-title":"Altered levels of MicroRNA-9, -206, and -132 in spinal muscular atrophy and their response to antisense oligonucleotide therapy","volume":"5","author":"Catapano","year":"2016","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"B19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3390\/antiox11020195","article-title":"Effects of the edaravone, a drug approved for the treatment of amyotrophic lateral sclerosis, on mitochondrial function and neuroprotection","volume":"11","author":"Cha","year":"2022","journal-title":"Antioxidants"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1007\/s00018-018-2849-1","article-title":"The role of survival motor neuron protein (SMN) in protein homeostasis","volume":"75","author":"Chaytow","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e70118","DOI":"10.1002\/cbf.70118","article-title":"Advances in the potential role and mechanism of fibroblasts in spinal muscular atrophy","volume":"43","author":"Chen","year":"2025","journal-title":"Cell Biochem. Funct."},{"key":"B22","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.1007\/s00415-024-12318-z","article-title":"JEWELFISH: 24-month results from an open-label study in non-treatment-na\u00efve patients with SMA receiving treatment with risdiplam","volume":"271","author":"Chiriboga","year":"2024","journal-title":"J. Neurology"},{"key":"B23","unstructured":"An open-label study to assess the safety and tolerability of a single intrathecal dose of ISIS 396443 in patients with spinal muscular atrophy who previously participated in ISIS 396443-CS1"},{"key":"B24","article-title":"An open-label study to assess the safety and tolerability of ISIS 396443","volume-title":"Patients with Spinal Muscular Atrophy who Previously Participated in 396443-CS2 or 396443-CS10","year":""},{"key":"B25","unstructured":"A phase 3, randomized, double-blind, sham-procedure controlled study to assess the clinical efficacy and safety of ISIS 396443 administered intrathecally in patients with infantile-onset spinal muscular atrophy"},{"key":"B26","volume-title":"A long-term Follow-up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving AVXS-101","year":"2025"},{"key":"B27","unstructured":"A long-term extension study of Nusinersen (BIIB058) administered at higher doses in participants with spinal muscular atrophy who previously participated in an investigational study with Nusinersen"},{"key":"B28","unstructured":"A phase 3b study to evaluate higher dose Nusinersen (BIIB058) in patients with spinal muscular atrophy previously treated with Risdiplam"},{"key":"B29","article-title":"A two-part, seamless, multi-center, randomized, placebo-controlled, double-blind study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7204239 in combination with Risdiplam (RO7034067)","volume-title":"Patients with Spinal Muscular Atrophy","year":""},{"key":"B30","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1172\/JCI35432","article-title":"Neural stem cell transplantation can ameliorate the phenotype of a mouse model of spinal muscular atrophy","volume":"118","author":"Corti","year":"2008","journal-title":"J. Clin. Investigation"},{"key":"B31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.27853","article-title":"Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study","volume":"68","author":"Crawford","year":"2023","journal-title":"Muscle and Nerve"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e209151","DOI":"10.1212\/WNL.0000000000209151","article-title":"Safety and efficacy of apitegromab in patients with spinal muscular atrophy types 2 and 3: the phase 2 TOPAZ study","volume":"102","author":"Crawford","year":"2024","journal-title":"Neurology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"953620","DOI":"10.3389\/fncel.2022.953620","article-title":"The alteration of left ventricular strain in later-onset spinal muscular atrophy children","volume":"16","author":"Cui","year":"2022","journal-title":"Front. Cell. Neurosci."},{"key":"B34","unstructured":"Releases the 2025 annual state of SMA\n          \n          \n          2025"},{"key":"B35","first-page":"117","article-title":"Chapter 8 - spinal muscular atrophies","volume-title":"Neuromuscular Disorders of Infancy, Childhood, and Adolescence","author":"Darras","year":"2015"},{"key":"B36","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s40263-019-00656-w","article-title":"An integrated safety analysis of infants and children with symptomatic spinal muscular atrophy (SMA) treated with Nusinersen in seven clinical trials","volume":"33","author":"Darras","year":"2019","journal-title":"CNS Drugs"},{"key":"B37","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1186\/s12887-022-03671-x","article-title":"Advances and limitations for the treatment of spinal muscular atrophy","volume":"22","author":"Day","year":"2022","journal-title":"BMC Pediatrics"},{"key":"B39","doi-asserted-by":"publisher","first-page":"E4377","DOI":"10.1073\/pnas.1600015113","article-title":"Decreased function of survival motor neuron protein impairs endocytic pathways","volume":"113","author":"Dimitriadi","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B40","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1523\/JNEUROSCI.3631-10.2011","article-title":"The survival of motor neuron (SMN) protein interacts with the mRNA-Binding protein HuD and regulates localization of Poly(A) mRNA in primary motor neuron axons","volume":"31","author":"Fallini","year":"2011","journal-title":"J. Neurosci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1093\/hmg\/ddi168","article-title":"Gemins modulate the expression and activity of the SMN complex","volume":"14","author":"Feng","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"B42","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"key":"B43","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3233\/JND-221560","article-title":"Intrathecal onasemnogene abeparvovec for sitting, nonambulatory patients with spinal muscular atrophy: phase I ascending-dose study (STRONG)","volume":"10","author":"Finkel","year":"2023","journal-title":"J. Neuromuscular Diseases"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1056\/NEJMc2300802","article-title":"Risdiplam for prenatal therapy of spinal muscular atrophy","volume":"392","author":"Finkel","year":"","journal-title":"N. Engl. J. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1056\/NEJMoa2410120","article-title":"Risdiplam in presymptomatic spinal muscular atrophy","volume":"393","author":"Finkel","year":"","journal-title":"N. Engl. J. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/s41591-025-04193-6","article-title":"High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial","volume":"32","author":"Finkel","year":"2026","journal-title":"Nat. Med."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2024.07.044","article-title":"137P mortality in spinal muscular atrophy in the era of disease-modifying therapies","volume":"43","author":"Finnegan","year":"2024","journal-title":"Neuromuscul. Disord."},{"key":"B48","doi-asserted-by":"publisher","first-page":"113041","DOI":"10.1016\/j.expneurol.2019.113041","article-title":"CSF transplantation of a specific iPSC-derived neural stem cell subpopulation ameliorates the disease phenotype in a mouse model of spinal muscular atrophy with respiratory distress type 1","volume":"321","author":"Forotti","year":"2019","journal-title":"Exp. Neurology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2008","journal-title":"Nat. Biotechnology"},{"key":"B50","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.mcn.2014.12.005","article-title":"Pluripotent stem cell-based models of spinal muscular atrophy","volume":"64","author":"Frattini","year":"2015","journal-title":"Mol. Cell. Neurosci."},{"key":"B51","doi-asserted-by":"publisher","first-page":"106443","DOI":"10.1016\/j.nmd.2026.106443","article-title":"Swallowing assessment in spinal muscular atrophy type 1: a real-world study of dysphagia in children receiving disease-modifying therapies","volume":"64","author":"Gandolfi","year":"2026","journal-title":"Neuromuscul. Disorders NMD"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1695359","DOI":"10.3389\/fnins.2025.1695359","article-title":"An induced pluripotent stem cell-based chemical genetic approach for studying spinal muscular atrophy","volume":"19","author":"Giadone","year":"2026","journal-title":"Front. Neurosci."},{"key":"B53","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/345823a0","article-title":"Genetic homogeneity between acute and chronic forms of spinal muscular atrophy","volume":"345","author":"Gilliam","year":"1990","journal-title":"Nature"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1093\/nar\/gkl374","article-title":"Depletion of SMN by RNA interference in HeLa cells induces defects in Cajal body formation","volume":"34","author":"Girard","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"B137","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1523\/JNEUROSCI.5775-11.2012","article-title":"Motor neuron rescue in spinal muscular atrophy mice demonstrates that sensory-motor defects are a consequence, not a cause, of motor neuron dysfunction","volume":"32","author":"Gogliotti","year":"2012","journal-title":"J. Neurosci."},{"key":"B55","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s00412-017-0637-6","article-title":"UsnRNP biogenesis: mechanisms and regulation","volume":"126","author":"Gruss","year":"2017","journal-title":"Chromosoma"},{"key":"B56","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.yexcr.2004.03.022","article-title":"The SMN complex","volume":"296","author":"Gubitz","year":"2004","journal-title":"Exp. Cell Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1177\/0883073815627882","article-title":"Intrathecal injections in children with spinal muscular atrophy: nusinersen clinical trial experience","volume":"31","author":"Hach\u00e9","year":"2016","journal-title":"J. Child Neurology"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-026-02175-x","article-title":"Characterisation of the SMN1\/2 locus using a highly specific variant caller on whole-genome sequence data from 500,000 individuals","author":"Hall","year":"2026","journal-title":"Eur. J. Hum. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.ajhg.2008.01.014","article-title":"Antisense masking of an hnRNP A1\/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice","volume":"82","author":"Hua","year":"2008","journal-title":"Am. J. Hum. Genet."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes and Development"},{"key":"B62","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1093\/hmg\/ddz142","article-title":"AAV9-mediated delivery of miR-23a reduces disease severity in Smn2B\/\u2212SMA model mice","volume":"28","author":"Kaifer","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"B63","doi-asserted-by":"publisher","first-page":"25579","DOI":"10.52965\/001c.25579","article-title":"Risdiplam for the use of spinal muscular atrophy","volume":"13","author":"Kakazu","year":"2021","journal-title":"Orthop. Rev."},{"key":"B64","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1093\/hmg\/ddn156","article-title":"Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy","volume":"17","author":"Kariya","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1093\/hmg\/ddi130","article-title":"The role of histone acetylation in SMN gene expression","volume":"14","author":"Kernochan","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"B66","article-title":"Modeling spinal muscular atrophy with patient derived iPSCs to characterize the role of SMN in cardiomyocytes and microglia","author":"Khayrullina","year":"2021"},{"key":"B67","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13395-020-00232-7","article-title":"SMN-deficiency disrupts SERCA2 expression and intracellular Ca2+ signaling in cardiomyocytes from SMA mice and patient-derived iPSCs","volume":"10","author":"Khayrullina","year":"2020","journal-title":"Skelet. Muscle"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1007\/s12325-024-02845-6","article-title":"Long-term comparative efficacy and safety of Risdiplam and Nusinersen in children with type 1 spinal muscular atrophy","volume":"41","author":"Kokaliaris","year":"2024","journal-title":"Adv. Ther."},{"key":"B69","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1523\/JNEUROSCI.4434-08.2009","article-title":"Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice","volume":"29","author":"Kong","year":"2009","journal-title":"J. Neurosci."},{"key":"B70","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41591-025-04119-2","article-title":"Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial","volume":"32","author":"Kwon","year":"2026","journal-title":"Nat. Medicine"},{"key":"B71","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1080\/15476286.2016.1231360","article-title":"Cajal bodies in neurons","volume":"14","author":"Lafarga","year":"2017","journal-title":"RNA Biol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.ydbio.2011.05.667","article-title":"Muscles in a mouse model of spinal muscular atrophy show profound defects in neuromuscular development even in the absence of failure in neuromuscular transmission or loss of motor neurons","volume":"356","author":"Lee","year":"2011","journal-title":"Dev. Biol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"B74","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/nsr\/nwz131","article-title":"Disruption of splicing-regulatory elements using CRISPR\/Cas9 to rescue spinal muscular atrophy in human iPSCs and mice","volume":"7","author":"Li","year":"2019","journal-title":"Natl. Sci. Rev."},{"key":"B75","doi-asserted-by":"publisher","first-page":"45476","DOI":"10.1074\/jbc.M107632200","article-title":"Modulation of survival motor neuron pre-mRNA splicing by inhibition of alternative 3' splice site pairing","volume":"276","author":"Lim","year":"2001","journal-title":"J. Biol. Chem."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S0092-8674(00)80367-0","article-title":"The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal snRNP proteins","volume":"90","author":"Liu","year":"1997","journal-title":"Cell"},{"key":"B77","doi-asserted-by":"publisher","first-page":"12189","DOI":"10.1038\/srep12189","article-title":"Spinal muscular atrophy patient-derived motor neurons exhibit hyperexcitability","volume":"5","author":"Liu","year":"2015","journal-title":"Sci. Rep."},{"key":"B78","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/hmg\/9.2.259","article-title":"An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN","volume":"9","author":"Lorson","year":"2000","journal-title":"Hum. Mol. Genet."},{"key":"B79","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy | PNAS","volume":"96","author":"Lorson","year":"1999","journal-title":"PNAS"},{"key":"B80","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.cell.2012.09.012","article-title":"An SMN-dependent U12 splicing event essential for motor circuit function","volume":"151","author":"Lotti","year":"2012","journal-title":"Cell"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.cell.2012.08.020","article-title":"Long-distance growth and connectivity of neural stem cells after severe spinal cord injury","volume":"150","author":"Lu","year":"2012","journal-title":"Cell"},{"key":"B82","doi-asserted-by":"publisher","first-page":"7319","DOI":"10.1073\/pnas.1701597114","article-title":"Poor caregiver mental health predicts mortality of patients with neurodegenerative disease","volume":"114","author":"Lwi","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/S1474-4422(22)00339-8","article-title":"Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial","volume":"21","author":"Masson","year":"2022","journal-title":"Lancet. Neurology"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1097\/BRS.0b013e3182194937","article-title":"Growing rods for scoliosis in spinal muscular atrophy: structural effects, complications, and hospital stays","volume":"36","author":"McElroy","year":"2011","journal-title":"Spine"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1038\/s12276-026-01689-0","article-title":"Haloperidol induces neuroprotection and enhances neuromuscular function in both murine and human models of spinal muscular atrophy","volume":"58","author":"Menduti","year":"2026","journal-title":"Exp. and Mol. Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus Sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"","journal-title":"N. Engl. J. Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"","journal-title":"Neuromuscul. Disord."},{"key":"B89","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","article-title":"Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"21","author":"Mercuri","year":"2022","journal-title":"Lancet. Neurology"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/hmg\/8.7.1177","article-title":"A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2","volume":"8","author":"Monani","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"B92","doi-asserted-by":"publisher","first-page":"8724","DOI":"10.1038\/s41467-025-64164-w","article-title":"Munc13-1 restoration mitigates presynaptic pathology in spinal muscular atrophy","volume":"16","author":"Moradi","year":"2025","journal-title":"Nat. Commun."},{"key":"B93","doi-asserted-by":"publisher","first-page":"126","DOI":"10.4252\/wjsc.v7.i1.126","article-title":"Adult human neural stem cell therapeutics: current developmental status and prospect","volume":"7","author":"Nam","year":"2015","journal-title":"World J. Stem Cells"},{"key":"B136","article-title":"Genes and Disease","volume-title":"Spinal muscular atrophy","year":"1998"},{"key":"B94","doi-asserted-by":"publisher","first-page":"11939","DOI":"10.3390\/ijms241511939","article-title":"Spinal muscular atrophy: the past, present, and future of diagnosis and treatment","volume":"24","author":"Nishio","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.36197","article-title":"Gene therapy for spinal muscular atrophy (SMA): a review of current challenges and safety considerations for Onasemnogene Abeparvovec (Zolgensma)","volume":"15","author":"Ogbonmide","year":"2023","journal-title":"Cureus"},{"key":"B96","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1038\/s41598-019-39788-w","article-title":"Notch signaling mediates Astrocyte abnormality in spinal muscular atrophy model systems","volume":"9","author":"Ohuchi","year":"2019","journal-title":"Sci. Rep."},{"key":"B97","doi-asserted-by":"publisher","first-page":"5948","DOI":"10.1093\/nar\/gkad259","article-title":"Diverse targets of SMN2-directed splicing-modulating small molecule therapeutics for spinal muscular atrophy","volume":"51","author":"Ottesen","year":"2023","journal-title":"Nucleic Acids Research"},{"key":"B98","doi-asserted-by":"publisher","first-page":"107324","DOI":"10.1016\/j.nbd.2026.107324","article-title":"Skeletal muscle in spinal muscular atrophy: critical insights from pathogenesis to therapeutic strategies","volume":"221","author":"Ottoboni","year":"2026","journal-title":"Neurobiol. Dis."},{"key":"B99","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1186\/s13023-024-03399-0","article-title":"Risdiplam utilization, adherence, and associated health care costs for patients with spinal muscular atrophy: a United States retrospective claims database analysis","volume":"19","author":"Patel","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1038\/s41591-024-03484-8","article-title":"First-in-human study of epidural spinal cord stimulation in individuals with spinal muscular atrophy","volume":"31","author":"Prat-Ortega","year":"2025","journal-title":"Nat. Med."},{"key":"B101","article-title":"Spinal muscular atrophy","volume-title":"Genereviews\u00ae","author":"Prior","year":"1993"},{"key":"B139","first-page":"1993","article-title":"A comprehensive view of global potential for hydro generated electricity","volume-title":"GeneReviews","author":"Prior","year":"2000"},{"key":"B102","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41591-025-04103-w","article-title":"Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial","volume":"32","author":"Proud","year":"2025","journal-title":"Nat. Med."},{"key":"B103","doi-asserted-by":"publisher","first-page":"942976","DOI":"10.3389\/fncel.2022.942976","article-title":"History of development of the life-saving drug \u201cNusinersen\u201d in spinal muscular atrophy","volume":"16","author":"Qiu","year":"2022","journal-title":"Front. Cell. Neurosci."},{"key":"B104","doi-asserted-by":"publisher","first-page":"125405","DOI":"10.1016\/j.jns.2025.125405","article-title":"Comparing the effectiveness of gene therapies for pediatric spinal muscular atrophy: Zolgensma, spinraza, and risdiplam","volume":"480","author":"Rathod","year":"2025","journal-title":"J. Neurological Sci."},{"key":"B105","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1021\/acsmedchemlett.0c00659","article-title":"Risdiplam, the first approved small molecule splicing modifier drug as a blueprint for future transformative medicines","volume":"12","author":"Ratni","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"B106","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41434-022-00349-y","article-title":"Curing SMA: are we there yet?","volume":"30","author":"Reilly","year":"2023","journal-title":"Gene Ther."},{"key":"B107","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s004390100473","article-title":"SMN gene duplication and the emergence of the SMN2 gene occurred in distinct hominids: SMN2 is unique to Homo sapiens","volume":"108","author":"Rochette","year":"2001","journal-title":"Hum. Genet."},{"key":"B108","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1083\/jcb.200304128","article-title":"Smn, the spinal muscular atrophy\u2013determining gene product, modulates axon growth and localization of \u03b2-actin mRNA in growth cones of motoneurons","volume":"163","author":"Rossoll","year":"2003","journal-title":"J. Cell Biol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1393779","DOI":"10.3389\/fnmol.2024.1393779","article-title":"Ptbp2 re-expression rescues axon growth defects in Smn-deficient motoneurons","volume":"17","author":"Salehi","year":"2024","journal-title":"Front. Molecular Neuroscience"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.3390\/cells14231852","article-title":"Targeting astrocytic connexin 43 mitigates glutamate-driven motor neuron stress in late-onset spinal muscular atrophy","volume":"14","author":"Salmanian","year":"2025","journal-title":"Cells"},{"key":"B111","doi-asserted-by":"publisher","first-page":"e39113","DOI":"10.1371\/journal.pone.0039113","article-title":"Inhibition of apoptosis blocks human motor neuron cell death in a stem cell model of spinal muscular atrophy","volume":"7","author":"Sareen","year":"2012","journal-title":"PLOS ONE"},{"key":"B112","doi-asserted-by":"publisher","first-page":"9920","DOI":"10.1073\/pnas.94.18.9920","article-title":"Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos","volume":"94","author":"Schrank","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B113","doi-asserted-by":"publisher","first-page":"9158","DOI":"10.1038\/s41598-021-88559-z","article-title":"Prenatal transplantation of human amniotic fluid stem cell could improve clinical outcome of type III spinal muscular atrophy in mice","volume":"11","author":"Shaw","year":"2021","journal-title":"Sci. Rep."},{"key":"B114","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.1016\/j.celrep.2017.12.003","article-title":"Converging mechanisms of p53 activation drive motor neuron degeneration in spinal muscular atrophy","volume":"21","author":"Simon","year":"2017","journal-title":"Cell Reports"},{"key":"B115","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1016\/j.celrep.2019.11.058","article-title":"Stasimon contributes to the loss of sensory synapses and motor neuron death in a mouse model of spinal muscular atrophy","volume":"29","author":"Simon","year":"2019","journal-title":"Cell Reports"},{"key":"B116","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.stemcr.2014.06.004","article-title":"iPSC-Derived neural stem cells act via kinase inhibition to exert neuroprotective effects in spinal muscular atrophy with respiratory distress type 1","volume":"3","author":"Simone","year":"2014","journal-title":"Stem Cell Rep."},{"key":"B117","doi-asserted-by":"publisher","first-page":"105","DOI":"10.22037\/ijcn.v12i1.12023","article-title":"Type 0 spinal muscular atrophy in rare association with congenital contracture and generalized osteopenia","volume":"12","author":"Singh","year":"2018","journal-title":"Iran. J. Child Neurology"},{"key":"B118","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1097\/MS9.0000000000002146","article-title":"Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR\/Cas9 gene therapy for sickle cell disease","volume":"86","author":"Singh","year":"2024","journal-title":"Ann. of Medicine Surgery"},{"key":"B119","volume-title":"Advocacy Groups","year":"2026"},{"key":"B120","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s13023-025-03888-w","article-title":"Rehabilitation management for patients with spinal muscular atrophy: a review","volume":"20","author":"Song","year":"2025","journal-title":"Orphanet J. Rare Dis."},{"key":"B121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/s41591-021-01483-7","article-title":"Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue","volume":"27","author":"Thomsen","year":"2021","journal-title":"Nat. Medicine"},{"key":"B123","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1080\/15476286.2016.1236169","article-title":"The Cajal body and the nucleolus: \u201cin a relationship\u201d or \u201cIt's complicated\u201d","volume":"14","author":"Trinkle-Mulcahy","year":"2016","journal-title":"RNA Biol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"268","DOI":"10.20517\/jtgg.2025.56","article-title":"SMN2 as a therapeutic target in spinal muscular atrophy: advances in gene expression modulation","volume":"9","author":"Virata","year":"2025","journal-title":"J. Transl. Genet. Genomics"},{"key":"B125","doi-asserted-by":"publisher","first-page":"296","DOI":"10.55275\/JPOSNA-2022-0006","article-title":"Best practices for the orthopaedic care of children with spinal muscular atrophy: a consensus statement from the european neuromuscular centre standard of care orthopaedic working group","volume":"4","author":"Vitale","year":"2022","journal-title":"J. Pediatr. Orthop. Soc. N. Am."},{"key":"B126","doi-asserted-by":"publisher","first-page":"103867","DOI":"10.1016\/j.eclinm.2026.103867","article-title":"Safety and efficacy of intravenous onasemnogene abeparvovec gene therapy in patients with spinal muscular atrophy type 1: interim analysis from LT-001, a long-term follow-up study of patients from the START study","volume":"94","author":"Waldrop","year":"2026","journal-title":"EClinicalMedicine"},{"key":"B127","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1177\/0883073807305788","article-title":"Consensus statement for standard of care in spinal muscular atrophy","volume":"22","author":"Wang","year":"2007","journal-title":"J. Child Neurology"},{"key":"B135","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"B128","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.3390\/nu17152561","article-title":"Difficulties of eating and masticating solid food in children with spinal muscular atrophy\u2014preliminary study","volume":"17","author":"Winnicka","year":"2025","journal-title":"Nutrients"},{"key":"B129","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/s44321-024-00037-x","article-title":"Improved gene therapy for spinal muscular atrophy in mice using codon-optimized hSMN1 transgene and hSMN1 gene-derived promotor","volume":"16","author":"Xie","year":"2024","journal-title":"EMBO Mol. Med."},{"key":"B130","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1097\/BRS.0000000000000383","article-title":"Improvement of pulmonary function in children with early-onset scoliosis using magnetic growth rods","volume":"39","author":"Yoon","year":"2014","journal-title":"Spine"},{"key":"B131","doi-asserted-by":"publisher","first-page":"19348","DOI":"10.1073\/pnas.1319280110","article-title":"Dysregulation of synaptogenesis genes antecedes motor neuron pathology in spinal muscular atrophy","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B132","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/ejhg.2012.293","article-title":"Genome-wide analysis shows association of epigenetic changes in regulators of Rab and Rho GTPases with spinal muscular atrophy severity","volume":"21","author":"Zheleznyakova","year":"2013","journal-title":"Eur. Journal Human Genetics EJHG"},{"key":"B133","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1089\/hum.2017.255","article-title":"Seamless genetic conversion of SMN2 to SMN1 via CRISPR\/Cpf1 and single-stranded oligodeoxynucleotides in spinal muscular atrophy patient-specific induced pluripotent stem cells","volume":"29","author":"Zhou","year":"2018","journal-title":"Hum. Gene Therapy"},{"key":"B134","doi-asserted-by":"publisher","first-page":"7941","DOI":"10.3390\/ijms23147941","article-title":"Targeted-deletion of a tiny sequence via prime editing to restore SMN expression","volume":"23","author":"Zhou","year":"2022","journal-title":"Int. J. Mol. Sci."}],"container-title":["Frontiers in Molecular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmmed.2026.1901311\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T09:58:20Z","timestamp":1787651900000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmmed.2026.1901311\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":137,"alternative-id":["10.3389\/fmmed.2026.1901311"],"URL":"https:\/\/doi.org\/10.3389\/fmmed.2026.1901311","relation":{},"ISSN":["2674-0095"],"issn-type":[{"value":"2674-0095","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"article-number":"1901311"}}